<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+8 6293ac&amp;ff=20230717124024&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC- &amp;utm_source=Chrome<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20230717124024&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 17 日星期一 16:40:25 +0000</lastbuilddate><pubDate> Mon, 17 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>电子烟和电子烟产品对心肺的影响：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37458106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>在过去的十年中，电子烟和电子烟的使用呈指数级增长，特别是在青少年中。吸烟是心血管疾病和肺部疾病的危险因素。电子烟和电子烟产品经常被吹捧为更安全的替代品以及潜在的戒烟产品。美国爆发了与电子烟或电子烟产品使用相关的肺损伤…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 17 日。doi：10.1161/CIR.0000000000001160。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在过去的十年中，电子烟和电子烟的使用呈指数级增长，特别是在青少年中。吸烟是心血管疾病和肺部疾病的危险因素。电子烟和电子烟产品经常被吹捧为更安全的替代品2019 年，美国爆发了与电子烟或电子烟产品使用相关的肺损伤，导致超过 2800 人住院，凸显了其中的风险。因此，无需进行药品或医疗器械所需的上市前动物和人类安全研究。2019 年美国高中生的使用率高达 27.5%，因此评估短期和长期的效果至关重要。这些产品对健康的长期影响，以及减少青少年使用的干预和公共卫生努力的发展。本科学声明的目标是（1）描述和讨论青少年和成人中电子烟和电子烟产品的使用模式； (2) 识别电子烟气溶胶中有害和潜在有害的成分；(3) 严格评估有关电子烟和电子烟产品使用的急性和慢性心血管和肺部风险的分子、动物和临床证据；(4)描述电子烟和电子烟产品作为潜在戒烟产品的当前证据；5) 总结当前电子烟和电子烟产品的公共卫生和监管工作。临床证据表明电子尼古丁输送系统会产生各种急性生理效应，特别是那些含有尼古丁的产品。随着这些产品的使用不断增长，迫切需要进行额外的临床和动物暴露模型研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37458106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37458106</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001160>10.1161/CIR.0000000000001160</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37458106</guid><pubDate> Mon, 17 Jul 2023 06:00:00 -0400</pubDate><dc:creator>杰森·J·罗斯</dc:creator><dc:creator>苏奇特拉·克里希南·沙林</dc:creator><dc:creator>韦尔纳·J·埃克西尔</dc:creator><dc:creator>——内奥米·汉堡</dc:creator><dc:creator>——杰西卡·L·费特曼</dc:creator><dc:creator>一之濑文人</dc:creator><dc:creator>米格尔·佩雷斯-平松更多</dc:creator><dc:creator>玛丽·雷兹克·汉娜</dc:creator><dc:creator>埃里克·威廉姆森</dc:creator><dc:creator>美国心脏协会心肺、重症监护、围手术期和复苏委员会；流行病学和预防委员会；心血管放射学和干预委员会；生活方式和心脏代谢健康委员会；血管生物学</dc:creator><dc:date>2023-07-17</dc:date><dc:source>循环</dc:source><dc:title>电子烟和电子烟产品对心肺的影响：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37458106</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001160</dc:identifier></item><item><title>国际医学期刊编辑委员会的新建议：人工智能的使用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37453047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 15:ehad448.doi: 10.1093/eurheartj/ehad448. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37453047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37453047</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad448>10.1093/eurheartj/ehad448</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37453047</guid><pubDate> Sat, 15 Jul 2023 06:00:00 -0400</pubDate><dc:creator>费尔南多·阿方索</dc:creator><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-07-15</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>国际医学期刊编辑委员会的新建议：人工智能的使用</dc:title><dc:identifier>下午：37453047</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad448</dc:identifier></item><item><title>人工智能通过经胸超声心动图检测左心耳血栓和临床特征：经食管超声心动图左心耳血栓 (LATTEE) 登记处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37453044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>结论：LAT-AI 可以准确预测 LAT。尽管存在慢性 OAC，但基于 LAT-AI 的方案可用于指导执行 TOE 的决定。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 15:ehad431.doi: 10.1093/eurheartj/ehad431. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：经食管超声心动图 (TOE) 通常在导管消融或心脏复律之前进行，以排除长期口服抗凝 (OAC) 患者左心耳血栓 (LAT) 的存在，尽管存在相关不适。智能 (AI)] 的开发是为了根据临床和经胸超声心动图 (TTE) 特征预测 LAT 的存在。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：使用了来自 13 个地点的前瞻性登记数据，这些患者在心脏复律或导管消融之前接受了 TOE。使用来自 12 个地点 (n = 2827) 的数据训练 LAT-AI 来预测 LAT，并在慢性病患者中进行外部测试。来自两个部位的 OAC (n = 1284)。将 LAT-AI 的受试者工作特征曲线 (AUC) 下的面积与左心室射血分数 (LVEF) 和 CHA2DS2-VASc 评分进行比较。允许 99% 的决策阈值在开发队列中定义了阴性预测值。在外部队列中验证了根据 LAT-AI 评分对慢性 OAC 患者进行 TOE 的方案。在外部测试队列中，5.5% 的患者发现了 LAT。 LAT-AI 的 AUC 为 0.85 [95% 置信区间 (CI)：0.82-0.89]，优于 LVEF（0.81，95% CI 0.76-0.86，P &lt; .0001）和 CHA2DS2-VASc 评分（0.69，95% CI） ). : 0.63-0.7, P &lt; .0001) 在整个外部队列中。根据提议的方案，外部队列中 40% 的慢性 OAC 患者将安全地避免 TOE。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：LAT-AI 可以准确预测 LAT。尽管存在慢性 OAC，但基于 LAT-AI 的方案可用于指导执行 TOE 的决定。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37453044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37453044</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad431>10.1093/eurheartj/ehad431</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37453044</guid><pubDate> Sat, 15 Jul 2023 06:00:00 -0400</pubDate><dc:creator>康拉德·皮埃什科</dc:creator><dc:creator>雅罗斯瓦夫·希茨凯维奇</dc:creator><dc:creator>卡塔齐娜·沃耶夫斯卡</dc:creator><dc:creator>贝亚塔·乌济布沃·日茨科斯卡</dc:creator><dc:creator>帕维尔·克热辛斯基</dc:creator><dc:creator>莫妮卡·川子</dc:creator><dc:creator>莫妮卡·布德尼克</dc:creator><dc:creator>卡塔齐娜·斯塔兹克</dc:creator><dc:creator>贝亚塔·沃扎科斯卡·卡普隆</dc:creator><dc:creator>卢德米拉·达尼沃维奇-希曼诺维奇</dc:creator><dc:creator>达米安·考夫曼</dc:creator><dc:creator>马切伊·沃伊西克</dc:creator><dc:creator>罗伯特·布拉兹奇克</dc:creator><dc:creator>卡塔齐娜·米齐亚·斯特克</dc:creator><dc:creator>马切伊·维布拉尼茨</dc:creator><dc:creator>卡塔齐娜·科斯玛斯卡</dc:creator><dc:creator>马尔辛·菲亚科夫斯基</dc:creator><dc:creator>安娜·席曼斯卡</dc:creator><dc:creator>米罗斯瓦夫·德卢日涅夫斯基</dc:creator><dc:creator>米哈乌·库西奥</dc:creator><dc:creator>马切伊·哈贝尔卡</dc:creator><dc:creator>卡罗琳娜·库普钦斯卡</dc:creator><dc:creator>布拉泽·米哈尔斯基</dc:creator><dc:creator>安娜·托马斯祖克-卡兹贝鲁克</dc:creator><dc:creator>卡塔齐娜·维尔克·谢莱兹耶夫斯卡</dc:creator><dc:creator>雷纳塔·沃奇尼卡·特鲁蒂</dc:creator><dc:creator>马雷克·科津斯基</dc:creator><dc:creator>雅采克·奎钦斯基</dc:creator><dc:creator>拉斐尔·沃尔尼</dc:creator><dc:creator>埃瓦·科瓦利克</dc:creator><dc:creator>Iga Kolasa更多</dc:creator><dc:creator>阿格涅斯卡·尤雷克</dc:creator><dc:creator>扬·布兹安诺夫斯基</dc:creator><dc:creator>帕维尔·伯查特</dc:creator><dc:creator>阿格涅斯卡·卡普翁-切斯利卡</dc:creator><dc:creator>彼得·J·斯洛姆卡</dc:creator><dc:date>2023-07-15</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>人工智能通过经胸超声心动图检测左心耳血栓和临床特征：经食管超声心动图左心耳血栓 (LATTEE) 登记处</dc:title><dc:identifier>下午：37453044</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad431</dc:identifier></item><item><title>急性肺栓塞的诊断管理：基于患者数据荟萃分析的预测模型</title><link/>https://pubmed.ncbi.nlm.nih.gov/37452732/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>结论：本模型提供了广泛的疑似 PE 患者群体中出现 PE 的绝对个体化概率，具有很好的区分度和校准性。其临床效用需要在前瞻性管理或影响研究中进行评估。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 15:ehad417.doi: 10.1093/eurheartj/ehad417. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：风险分层用于决定临床怀疑患有急性肺栓塞 (PE) 的患者是否需要进行影像学检查。目的是开发一种临床预测模型，为患有急性肺栓塞 (PE) 的患者提供个体化、准确的概率估计。根据现成的临床项目和 D-二聚体浓度怀疑患有疾病。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：基于 16 项横断面或前瞻性研究进行了个体患者数据荟萃分析，这些研究的数据来自不同临床环境的 28 305 名临床疑似 PE 的成年患者，包括初级保健、急诊、住院和疗养院患者建立并验证了多级逻辑回归模型，包括十个先验定义的客观候选预测因子，用于预测基线时客观确认的 PE 或 30 至 90 天随访期间的静脉血栓栓塞 (VTE)。对缺失数据使用多重插补。执行时 P 值 &lt;0.10。区分（具有 95% 置信区间 [CI] 和预测区间 [PI] 的 c 统计量）和校准（结果：预期 [O:E] 比率和校准图）基于内部-外部交叉验证。随后将模型的准确性与基于 Wells 评分和 D-二聚体测试的算法进行比较。最终模型包括年龄（以年为单位）、性别、既往 VTE、近期手术或制动、咯血、癌症、深静脉血栓形成的临床症状、住院状态、D-二聚体（以 µg/L 为单位）以及年龄和 D-二聚体之间的相互作用项。汇总的 c 统计量为 0.87（95% CI，0.85-0.89；95） % PI, 0.77-0.93），总体校准非常好（合并 O:E 比，0.99；95% CI，0.87-1.14；95% PI，0.55-1.79）。估计概率。当前模型的判别验证数据集优于 Wells 评分与基于年龄的 D-二聚体阈值（c 统计量 0.73；95% CI，0.70-0.75）或结构化临床预测试概率（c 统计量 0.79；95% CI， 0.76-0.81）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：本模型提供了广泛的疑似 PE 患者群体中出现 PE 的绝对个体化概率，具有很好的区分度和校准性。其临床效用需要在前瞻性管理或影响研究中进行评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：普洛斯彼罗 ID 89366。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37452732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37452732</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad417>10.1093/eurheartj/ehad417</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37452732</guid><pubDate> Sat, 15 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——尼克·范·埃斯</dc:creator><dc:creator>高田俊彦</dc:creator><dc:creator>诺埃米·克雷普尔</dc:creator><dc:creator>弗雷德里克斯·克洛克</dc:creator><dc:creator>米卢·AM·斯塔尔斯</dc:creator><dc:creator>哈里·R·布勒</dc:creator><dc:creator>D·马克·考特尼</dc:creator><dc:creator>约纳森·弗罗因德</dc:creator><dc:creator>哈维尔·加利平佐</dc:creator><dc:creator>格雷瓜尔·勒加尔</dc:creator><dc:creator>瓦利德·加尼玛</dc:creator><dc:creator>门诺 V 豪氏威马</dc:creator><dc:creator>杰弗里·克莱恩</dc:creator><dc:creator>卡雷尔 GM 月亮</dc:creator><dc:creator>萨米尔·帕皮亚</dc:creator><dc:creator>阿诺·巴黎水</dc:creator><dc:creator>马克·里吉尼</dc:creator><dc:creator>赫莉亚·罗伯特-埃巴迪</dc:creator><dc:creator>皮埃尔-玛丽·罗伊</dc:creator><dc:creator>菲尔斯·威尔斯</dc:creator><dc:creator>克斯坦·德·维特</dc:creator><dc:creator>马丁·范·斯梅登</dc:creator><dc:creator>吉尔特·扬·吉尔辛</dc:creator><dc:date>2023-07-15</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>急性肺栓塞的诊断管理：基于患者数据荟萃分析的预测模型</dc:title><dc:identifier>下午：37452732</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad417</dc:identifier></item><item><title>心力衰竭和社会经济地位：全球差异和不平等</title><link/>https://pubmed.ncbi.nlm.nih.gov/37452730/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 15:ehad410.doi: 10.1093/eurheartj/ehad410. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37452730/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37452730</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad410>10.1093/eurheartj/ehad410</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37452730</guid><pubDate> Sat, 15 Jul 2023 06:00:00 -0400</pubDate><dc:creator>罗科·维加罗</dc:creator><dc:creator>卡罗·帕特罗诺</dc:creator><dc:date>2023-07-15</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心力衰竭和社会经济地位：全球差异和不平等</dc:title><dc:identifier>下午：37452730</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad410</dc:identifier></item><item><title>心脏移植：扩大供体库和异种移植方面的进展</title><link/>https://pubmed.ncbi.nlm.nih.gov/37452122/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>全球大约有 6500 万成年人患有心力衰竭，并且随着人口老龄化，患病率预计将大幅增加。尽管心力衰竭的药物和设备治疗取得了进展，但长期发病率和死亡率仍然很高。许多患者进展为晚期心力衰竭并发展为晚期心力衰竭。心脏移植仍然是改善这些患者的生活质量、功能状态和生存率的金标准疗法。然而，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 7 月 14 日。doi：10.1038/s41569-023-00902-1。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">全球大约有 6500 万成年人患有心力衰竭，并且随着人口老龄化，患病率预计将大幅增加。尽管心力衰竭的药物和设备治疗取得了进展，但长期发病率和死亡率仍然很高。许多患者进展为晚期心力衰竭并发展为晚期心力衰竭。坚持心脏移植仍然是改善患者生活质量、功能状态和生存率的金标准治疗方法，但器官供应与心脏移植需求之间存在较大不平衡，供体库对于降低死亡率至关重要在等候名单上并改善该患者群体的临床结果。已经发生了转变，考虑使用来自丙型肝炎病毒、HIV 或 SARS-CoV-2 感染的捐献者的器官。该领域的其他进展也扩大了捐献者的范围我们对这些不同的新策略进行了全面的概述，提供了有关其安全性和有效性的客观数据，并讨论了每种方法中一些尚未解决的问题和争议。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37452122/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37452122</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00902-1>10.1038/s41569-023-00902-1</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37452122</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>斯蒂芬妮·朱</dc:creator><dc:creator>——肖恩·R·门德斯</dc:creator><dc:creator>贾森·费曼</dc:creator><dc:creator>林赛·R·米特拉尼</dc:creator><dc:creator>瓦伦丁·福斯特</dc:creator><dc:creator>马西莫·曼吉奥拉</dc:creator><dc:creator>Nader Moazami更多</dc:creator><dc:creator>克劳迪娅·吉迪亚</dc:creator><dc:date>2023-07-14</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>心脏移植：扩大供体库和异种移植方面的进展</dc:title><dc:identifier>下午：37452122</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00902-1</dc:identifier></item><item><title>素食和纯素饮食：优点和缺点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37450568/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>植物性饮食因其所谓的健康益处以及最近对环境的积极影响而变得越来越受欢迎。前瞻性研究表明，食用素食可降低患心血管疾病 (CVD)、糖尿病、高血压、痴呆症的风险，随机临床试验的数据已证实素食对于预防糖尿病以及减轻体重、血压等具有保护作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad436.doi: 10.1093/eurheartj/ehad436. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">植物性饮食因其所谓的健康益处以及最近对环境的积极影响而变得越来越受欢迎。前瞻性研究表明，食用素食可降低患心血管疾病 (CVD)、糖尿病、高血压、痴呆症的风险，随机临床试验的数据已证实素食对预防糖尿病以及降低体重、血压、糖化血红蛋白和低密度脂蛋白胆固醇具有保护作用，但迄今为止，还没有心血管事件发生率的数据。所有植物性食品都同样健康。不健康的素食饮食缺乏特定营养素（维生素 B12、铁、锌和钙）和/或富含高度加工的食品。需要进一步的机制研究来了解健康的、最低限度加工的素食是否具有优势饮食代表了一种全有或全无的现象，以及主要食用含有少量动物产品的植物性饮食（例如pesco素食或地中海饮食）是否对心脏代谢健康结果有有益、有害或中性影响。此外，机制研究是有必要增强我们对健康植物性食物模式以及与饮食因素、CVD 和其他代谢疾病相关的生物学机制的理解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37450568/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37450568</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad436>10.1093/eurheartj/ehad436</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37450568</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>王田</dc:creator><dc:creator>安德鲁斯·马塞敦斯卡斯</dc:creator><dc:creator>沃尔特·威利特</dc:creator><dc:creator>路易吉丰塔纳</dc:creator><dc:date>2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>素食和纯素饮食：优点和缺点</dc:title><dc:identifier>下午：37450568</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad436</dc:identifier></item><item><title> 《欧洲心脏杂志》的主要贡献机构：英国皇家布朗普顿医院和哈尔菲尔德医院</title><link/>https://pubmed.ncbi.nlm.nih.gov/37450561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad442.doi: 10.1093/eurheartj/ehad442. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37450561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37450561</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad442>10.1093/eurheartj/ehad442</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37450561</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>《欧洲心脏杂志》的主要贡献机构：英国皇家布朗普顿医院和哈尔菲尔德医院</dc:title><dc:identifier>下午：37450561</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad442</dc:identifier></item><item><title>心房颤动相关基因 &lt;em>;Zfhx3&lt;/em>; 的丢失会导致心房扩张和心律失常</title><link/>https://pubmed.ncbi.nlm.nih.gov/37449401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>结论：我们的研究结果表明 ZFHX3 是 16q22 位点上 AF 的致病基因，心脏 Zfhx3 缺失引起的心脏异常是由于参与 AF 易感性的心房特异性通路失调所致。总而言之，这些数据揭示了一种新颖且重要的作用Zfhx3 控制正常心房功能所必需的心脏基因和信号通路。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 14 日。doi：10.1161/CIRCRESAHA.123.323029。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景： <i>ZFHX3</i>是一种编码大转录因子的基因，是与心房颤动（AF）第二显着相关的位点，但其在心脏中的功能尚不清楚。本研究旨在确定与 AF 相关的致病遗传变异。 <i>ZFHX3</i>基因座并检查<i>Zfhx3</i>缺失对小鼠心脏功能的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在多能干细胞衍生的心肌细胞中使用 CRISPR-Cas9 基因组编辑、染色质免疫沉淀和荧光素酶测定来识别<i>ZFHX3</i>位点与 AF 相关的致病遗传变异。通过超声心动图、磁共振成像、电生理学研究、对杂合子和纯合子心肌细胞限制性<i>Zfhx3</i>缺失（分别为<i>Zfhx3</i> Het 和敲除）小鼠进行钙成像和 RNA 测序。分析人心脏单核 ATAC 测序数据，以确定心房心肌细胞中的哪些基因直接受<i>ZFHX3</i>调节。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现 SNP rs12931021 调节<i>ZFHX3</i>表达的增强子，并且 AF 风险等位基因与<i>ZFHX3</i>转录减少相关。我们观察到 Zfhx3 敲除小鼠的 AF 易感性基因剂量反应，其 AF 发生率、频率和负担高于<i>Zfhx3</i> Het 和野生型小鼠，传导速度、心房动作电位持续时间、钙处理以及心房扩大和血栓以及扩张型心肌病的发生发生变化<i>。Zfhx3</i>缺失导致心房特异性差异效应，涉及相关基因和信号通路心脏病理生理学和 AF。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究结果表明<i>ZFHX3</i>是 16q22 位点上 AF 的致病基因，心脏<i>Zfhx3</i>缺失引起的心脏异常是由于参与 AF 易感性的心房特异性通路失调所致。总而言之，这些数据揭示了一种新颖且重要的作用<i>Zfhx3</i>控制正常心房功能所必需的心脏基因和信号通路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37449401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37449401</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323029>10.1161/CIRCRESAHA.123.323029</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37449401</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>希瑟·詹姆森</dc:creator><dc:creator>——艾伦·汉利</dc:creator><dc:creator>——马修·C·希尔</dc:creator><dc:creator>凌霄</dc:creator><dc:creator>叶江川</dc:creator><dc:creator>阿尼什·巴帕特</dc:creator><dc:creator>埃尔莎·罗齐尔</dc:creator><dc:creator>阿米莉亚·韦伯·霍尔</dc:creator><dc:creator>——威廉·J·哈克</dc:creator><dc:creator>塞巴斯蒂安·克劳斯</dc:creator><dc:creator>米兰达·巴拉扎</dc:creator><dc:creator>伊丽莎白·西尔伯</dc:creator><dc:creator>朱莉·米娜</dc:creator><dc:creator>——内森·R·塔克</dc:creator><dc:creator>——罗伯特·W·米尔斯</dc:creator><dc:creator>董金堂</dc:creator><dc:creator>大卫·J·米兰</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:date>2023-07-14</dc:date><dc:source>流通研究</dc:source><dc:title>心房颤动相关基因 &lt;em>;Zfhx3&lt;/em>; 的丢失会导致心房扩张和心律失常</dc:title><dc:identifier>下午：37449401</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323029</dc:identifier></item><item><title>消除动脉粥样硬化性心血管疾病的残余风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37448228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad446.doi: 10.1093/eurheartj/ehad446. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37448228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37448228</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad446>10.1093/eurheartj/ehad446</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37448228</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——迈克尔·E·马科弗</dc:creator><dc:creator>斯坦尼斯瓦夫·苏尔马</dc:creator><dc:creator>马切伊·巴纳赫</dc:creator><dc:creator>彼得·P·托特</dc:creator><dc:date>2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>消除动脉粥样硬化性心血管疾病的残余风险</dc:title><dc:identifier>下午：37448228</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad446</dc:identifier></item><item><title>心脏代谢风险管理：欧洲心脏病学会心血管圆桌会议的见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37448181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>代谢合并症在心肾疾病患者中很常见；它们可导致动脉粥样硬化性心血管疾病 (ASCVD)，加速病情进展并对预后产生不利影响。常见合并症包括 2 型糖尿病 (T2DM)、肥胖/超重、慢性肾脏病 (CKD)、心血管系统、肾脏和肝脏与许多相同的危险因素有关（例如血脂异常、高血压、吸烟、糖尿病和中央/躯干肥胖），... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad445.doi: 10.1093/eurheartj/ehad445. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">代谢合并症在心肾疾病患者中很常见；它们可导致动脉粥样硬化性心血管疾病 (ASCVD)，加速病情进展并对预后产生不利影响。常见合并症包括 2 型糖尿病 (T2DM)、肥胖/超重、慢性肾脏病 (CKD)、心血管系统、肾脏和肝脏与许多相同的危险因素有关（例如血脂异常、高血压、吸烟、糖尿病和中央/躯干肥胖），并且共同的代谢和功能异常会导致全身损害。这些器官通过重叠病理生理学途径。COVID-19 大流行使心脏代谢疾病的管理进一步复杂化。肥胖、T2DM、CKD 和肝病与 COVID-19 感染不良结局的风险增加相关，相反，COVID-19 可能导致病情恶化这些合并症的高发生率凸显了需要提高肥胖、胰岛素抵抗或 T2DM、慢性肝病和 CKD 患者对 ASCVD 的认识和治疗，同样，需要提高对这些疾病的认识和治疗ASCVD 患者。预防和管理心脏代谢疾病的策略包括生活方式改变、药物治疗和手术。社会层面需要更多的计划来鼓励健康饮食和身体活动。可以针对跨疾病的多种病理生理途径的方法。非手术和手术减肥策略可以改善肥胖症患者的心脏代谢紊乱。正在研究的新生物标志物可能有助于早期识别处于危险中的个体并揭示新的治疗目标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37448181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37448181</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad445>10.1093/eurheartj/ehad445</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37448181</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>弗朗西斯科·科森蒂诺</dc:creator><dc:creator>Subodh Verma更多</dc:creator><dc:creator>菲利普·安伯里</dc:creator><dc:creator>玛丽安·巴赫·特雷彭达尔</dc:creator><dc:creator>马丁·范·艾克斯</dc:creator><dc:creator>斯特凡·D·安克</dc:creator><dc:creator>米歇尔·切基尼</dc:creator><dc:creator>保拉·菲奥雷托</dc:creator><dc:creator>佩尔·亨里克·格鲁普</dc:creator><dc:creator>大卫·赫斯</dc:creator><dc:creator>卡姆莱什·昆蒂</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>伊莎贝尔·理查德·洛德罗</dc:creator><dc:creator>拉尔斯·H·隆德</dc:creator><dc:creator>保罗·麦克格里维</dc:creator><dc:creator>菲利普·纽瑟姆</dc:creator><dc:creator>纳维德·萨塔尔</dc:creator><dc:creator>斯科特·所罗门</dc:creator><dc:creator>弗朗茨·魏丁格</dc:creator><dc:creator>Faiez Zannad更多</dc:creator><dc:creator>安德烈亚斯·泽赫</dc:creator><dc:date>2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心脏代谢风险管理：欧洲心脏病学会心血管圆桌会议的见解</dc:title><dc:identifier>下午：37448181</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad445</dc:identifier></item><item><title> FGF23 和 klotho 处于肾脏和心血管疾病的交叉点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37443358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>心血管疾病是慢性肾病 (CKD) 患者死亡的主要原因。随着 CKD 的进展，CKD 特有的危险因素（例如矿物质稳态紊乱）会放大传统的心血管危险因素。成纤维细胞生长因子 23 (FGF23) 调节矿物质稳态通过激活 FGF 受体和跨膜 klotho 辅助受体的复合物。可溶形式的 klotho 还在不表达 klotho 的组织中充当“便携式”FGF23 辅助受体。在... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 7 月 13 日。doi：10.1038/s41569-023-00903-0。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心血管疾病是慢性肾病 (CKD) 患者死亡的主要原因。随着 CKD 的进展，CKD 特有的危险因素（例如矿物质稳态紊乱）会放大传统的心血管危险因素。成纤维细胞生长因子 23 (FGF23) 调节矿物质稳态通过激活 FGF 受体和跨膜 klotho 辅助受体的复合物。klotho 的可溶形式也可在不表达 klotho 的组织中充当“便携式”FGF23 辅助受体。在进行性 CKD 中，循环 FGF23 水平升高与肾功能下降相结合klotho 的表达导致 FGF23 对心脏产生独立于 klotho 的影响，从而促进左心室肥大、心力衰竭、心房颤动和死亡。新出现的数据表明，可溶性 klotho 可能通过几种候选机制减轻其中一些影响。需要更多的研究来证实研究 CKD 特定心血管并发症中的 FGF23 过量和 klotho 缺乏，但考虑到 FGF23 过量与 klotho 缺乏共同的纠缠反馈环路，FGF23 过量与 klotho 缺乏的病理生理学首要地位可能永远不会得到精确解决。因此，随机试验应优先考虑临床实用性而不是科学确定性：全面针对矿物质稳态紊乱，努力改善 CKD 患者的心血管结局。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37443358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37443358</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00903-0>10.1038/s41569-023-00903-0</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37443358</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·埃德蒙斯顿</dc:creator><dc:creator>亚历山大·格拉布纳</dc:creator><dc:creator>迈尔斯·沃尔夫</dc:creator><dc:date>2023-07-14</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>FGF23 和 klotho 处于肾脏和心血管疾病的交叉点</dc:title><dc:identifier>下午：37443358</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00903-0</dc:identifier></item><item><title>应对心房颤动的流行：优化导管消融和新的治疗靶点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37442559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 7 月 14 日；44(27):2413-2416.doi: 10.1093/eurheartj/ehad438。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37442559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37442559</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad438>10.1093/eurheartj/ehad438</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37442559</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-07-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>应对心房颤动的流行：优化导管消融和新的治疗靶点</dc:title><dc:identifier>下午：37442559</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad438</dc:identifier></item><item><title>单细胞空间转录组揭示了猕猴皮层的细胞类型组织</title><link/>https://pubmed.ncbi.nlm.nih.gov/37442136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230717124024&amp;v=2.17.9.post6+86293ac<description>通过对 143 个猕猴皮层区域进行大规模单核 RNA 测序和空间转录组分析，我们获得了 264 个转录组定义的皮层细胞类型的综合图谱，并描述了皮层层和谷氨酸能、GABA 能和非神经元的区域偏好细胞... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 7 日：S0092-8674(23)00679-7.doi: 10.1016/j.cell.2023.06.009.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Elucidating the cellular organization of the cerebral cortex is critical for understanding brain structure and function. Using large-scale single-nucleus RNA sequencing and spatial transcriptomic analysis of 143 macaque cortical regions, we obtained a comprehensive atlas of 264 transcriptome-defined cortical cell types and mapped their spatial distribution across the entire cortex. We characterized the cortical layer and region preferences of glutamatergic, GABAergic, and non-neuronal cell types, as well as regional differences in cell-type composition and neighborhood complexity. Notably, we discovered a relationship between the regional distribution of various cell types and the region&#39;s hierarchical level in the visual and somatosensory systems. Cross-species comparison of transcriptomic data from human, macaque, and mouse cortices further revealed primate-specific cell types that are enriched in layer 4, with their marker genes expressed in a region-dependent manner. Our data provide a cellular and molecular basis for understanding the evolution, development, aging, and pathogenesis of the primate brain.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37442136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37442136</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.06.009>10.1016/j.cell.2023.06.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37442136</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Ao Chen</dc:creator><dc:creator> Yidi Sun</dc:creator><dc:creator> Ying Lei</dc:creator><dc:creator> Chao Li</dc:creator><dc:creator> Sha Liao</dc:creator><dc:creator> Juan Meng</dc:creator><dc:creator> Yiqin Bai</dc:creator><dc:creator> Zhen Liu</dc:creator><dc:creator> Zhifeng Liang</dc:creator><dc:creator> Zhiyong Zhu</dc:creator><dc:creator> Nini Yuan</dc:creator><dc:creator> Hao Yang</dc:creator><dc:creator> Zihan Wu</dc:creator><dc:creator> Feng Lin</dc:creator><dc:creator> Kexin Wang</dc:creator><dc:creator> Mei Li</dc:creator><dc:creator> Shuzhen Zhang</dc:creator><dc:creator> Meisong Yang</dc:creator><dc:creator> Tianyi Fei</dc:creator><dc:creator> Zhenkun Zhuang</dc:creator><dc:creator> Yiming Huang</dc:creator><dc:creator> Yong Zhang</dc:creator><dc:creator> Yuanfang Xu</dc:creator><dc:creator> Luman Cui</dc:creator><dc:creator> Ruiyi Zhang</dc:creator><dc:creator> Lei Han</dc:creator><dc:creator> Xing Sun</dc:creator><dc:creator> Bichao Chen</dc:creator><dc:creator> Wenjiao Li</dc:creator><dc:creator> Baoqian Huangfu</dc:creator><dc:creator> Kailong Ma</dc:creator><dc:creator> Jianyun Ma</dc:creator><dc:creator> Zhao Li</dc:creator><dc:creator> Yikun Lin</dc:creator><dc:creator> He Wang</dc:creator><dc:creator> Yanqing Zhong</dc:creator><dc:creator> Huifang Zhang</dc:creator><dc:creator> Qian Yu</dc:creator><dc:creator> Yaqian Wang</dc:creator><dc:creator> Xing Liu</dc:creator><dc:creator> Jian Peng</dc:creator><dc:creator> Chuanyu Liu</dc:creator><dc:creator> Wei Chen</dc:creator><dc:creator> Wentao Pan</dc:creator><dc:creator> Yingjie An</dc:creator><dc:creator> Shihui Xia</dc:creator><dc:creator> Yanbing Lu</dc:creator><dc:creator> Mingli Wang</dc:creator><dc:creator> Xinxiang Song</dc:creator><dc:creator> Shuai Liu</dc:creator><dc:creator> Zhifeng Wang</dc:creator><dc:creator> Chun Gong</dc:creator><dc:creator> Xin Huang</dc:creator><dc:creator> Yue Yuan</dc:creator><dc:creator> Yun Zhao</dc:creator><dc:creator> Qinwen Chai</dc:creator><dc:creator> Xing Tan</dc:creator><dc:creator> Jianfeng Liu</dc:creator><dc:creator> Mingyuan Zheng</dc:creator><dc:creator> Shengkang Li</dc:creator><dc:creator> Yaling Huang</dc:creator><dc:creator> Yan Hong</dc:creator><dc:creator> Zirui Huang</dc:creator><dc:creator> Min Li</dc:creator><dc:creator> Mengmeng Jin</dc:creator><dc:creator> Yan Li</dc:creator><dc:creator> Hui Zhang</dc:creator><dc:creator> Suhong Sun</dc:creator><dc:creator> Li Gao</dc:creator><dc:creator> Yinqi Bai</dc:creator><dc:creator> Mengnan Cheng</dc:creator><dc:creator> Guohai Hu</dc:creator><dc:creator> Shiping Liu</dc:creator><dc:creator> Bo Wang</dc:creator><dc:creator> Bin Xiang</dc:creator><dc:creator> Shuting Li</dc:creator><dc:creator> Huanhuan Li</dc:creator><dc:creator> Mengni Chen</dc:creator><dc:creator> Shiwen Wang</dc:creator><dc:creator> Minglong Li</dc:creator><dc:creator> Weibin Liu</dc:creator><dc:creator> Xin Liu</dc:creator><dc:creator> Qian Zhao</dc:creator><dc:creator> Michael Lisby</dc:creator><dc:creator> Jing Wang</dc:creator><dc:creator> Jiao Fang</dc:creator><dc:creator> Yun Lin</dc:creator><dc:creator> Qing Xie</dc:creator><dc:creator> Zhen Liu</dc:creator><dc:creator> Jie He</dc:creator><dc:creator> Huatai Xu</dc:creator><dc:creator> Wei Huang</dc:creator><dc:creator> Jan Mulder</dc:creator><dc:creator> Huanming Yang</dc:creator><dc:creator> Yangang Sun</dc:creator><dc:creator> Mathias Uhlen</dc:creator><dc:creator> Muming Poo</dc:creator><dc:creator> Jian Wang</dc:creator><dc:creator> Jianhua Yao</dc:creator><dc:creator> Wu Wei</dc:creator><dc:creator> Yuxiang Li</dc:creator><dc:creator> Zhiming Shen</dc:creator><dc:creator> Longqi Liu</dc:creator><dc:creator> Zhiyong Liu</dc:creator><dc:creator> Xun Xu</dc:creator><dc:creator> Chengyu Li</dc:creator><dc:date> 2023-07-13</dc:date><dc:source> Cell</dc:source><dc:title> Single-cell spatial transcriptome reveals cell-type organization in the macaque cortex</dc:title><dc:identifier> pmid:37442136</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.009</dc:identifier></item><item><title> Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37439553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> Patients with severe infections and a pre-existing indication for antithrombotic therapy, ie antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical counselling among coagulation, infectious disease, and cardiology specialists, due to sepsis-induced coagulopathy that frequently occurs. Bacterial and viral pathogens constitute an increasing threat to global public health, especially for patients with ongoing antithrombotic treatment who have a high risk of... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 13:ehad388. doi: 10.1093/eurheartj/ehad388. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patients with severe infections and a pre-existing indication for antithrombotic therapy, ie antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical counselling among coagulation, infectious disease, and cardiology specialists, due to sepsis-induced coagulopathy that frequently occurs. Bacterial and viral pathogens constitute an increasing threat to global public health, especially for patients with ongoing antithrombotic treatment who have a high risk of thrombotic recurrences and high susceptibility to severe infections with increased morbidity and mortality. Similarly, sepsis survivors are at increased risk for major vascular events. Coagulopathy, which often complicates severe infections, is associated with a high mortality and obligates clinicians to adjust antithrombotic drug type and dosing to avoid bleeding while preventing thrombotic complications. This clinical consensus statement reviews the best available evidence to provide expert opinion and statements on the management of patients hospitalized for severe bacterial or viral infections with a pre-existing indication for antithrombotic therapy (single or combined), in whom sepsis-induced coagulopathy is often observed. Balancing the risk of thrombosis and bleeding in these patients and preventing infections with vaccines, if available, are crucial to prevent events or improve outcomes and prognosis.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37439553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37439553</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad388>10.1093/eurheartj/ehad388</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37439553</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Bruna Gigante</dc:creator><dc:creator> Jerrold H Levy</dc:creator><dc:creator> Eric van Gorp</dc:creator><dc:creator> Alessandro Bartoloni</dc:creator><dc:creator> Marie-Luce Bochaton-Piallat</dc:creator><dc:creator> Magnus Bäck</dc:creator><dc:creator> Hugo Ten Cate</dc:creator><dc:creator> Christina Christersson</dc:creator><dc:creator> José Luis Ferreiro</dc:creator><dc:creator> Tobias Geisler</dc:creator><dc:creator> Esther Lutgens</dc:creator><dc:creator> Sam Schulman</dc:creator><dc:creator> Robert F Storey</dc:creator><dc:creator> Jecko Thachil</dc:creator><dc:creator> Gemma Vilahur</dc:creator><dc:creator> Patricia C Liaw</dc:creator><dc:creator> Bianca Rocca</dc:creator><dc:date> 2023-07-13</dc:date><dc:source> European heart journal</dc:source><dc:title> Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis</dc:title><dc:identifier> pmid:37439553</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad388</dc:identifier></item><item><title> Impact of BNT162b2 and mRNA-1273 Vaccination on Vascular Function in Healthy Adults: A Pilot Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37439257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Jul 13. doi: 10.1161/CIRCRESAHA.122.322862. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37439257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37439257</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.122.322862>10.1161/CIRCRESAHA.122.322862</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37439257</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Corinna Serviente</dc:creator><dc:creator> Alexs Matias</dc:creator><dc:creator> Mia Calderone</dc:creator><dc:creator> Muhammet Enes Erol</dc:creator><dc:creator> Stuart Chipkin</dc:creator><dc:creator> Gwenael Layec</dc:creator><dc:date> 2023-07-13</dc:date><dc:source> Circulation research</dc:source><dc:title> Impact of BNT162b2 and mRNA-1273 Vaccination on Vascular Function in Healthy Adults: A Pilot Study</dc:title><dc:identifier> pmid:37439257</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322862</dc:identifier></item><item><title> Dual-Organ Transplantation: Indications, Evaluation, and Outcomes for Heart-Kidney and Heart-Liver Transplantation: A Scientific Statement From the American Heart Association</title><link/> https://pubmed.ncbi.nlm.nih.gov/37439224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> Although heart transplantation is the preferred therapy for appropriate patients with advanced heart failure, the presence of concomitant renal or hepatic dysfunction can pose a barrier to isolated heart transplantation. Because donor organ supply limits the availability of organ transplantation, appropriate allocation of this scarce resource is essential; thus, clear guidance for simultaneous heart-kidney transplantation and simultaneous heart-liver transplantation is urgently required. The... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Jul 13. doi: 10.1161/CIR.0000000000001155. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Although heart transplantation is the preferred therapy for appropriate patients with advanced heart failure, the presence of concomitant renal or hepatic dysfunction can pose a barrier to isolated heart transplantation. Because donor organ supply limits the availability of organ transplantation, appropriate allocation of this scarce resource is essential; thus, clear guidance for simultaneous heart-kidney transplantation and simultaneous heart-liver transplantation is urgently required. The purposes of this scientific statement are (1) to describe the impact of pretransplantation renal and hepatic dysfunction on posttransplantation outcomes; (2) to discuss the assessment of pretransplantation renal and hepatic dysfunction; (3) to provide an approach to patient selection for simultaneous heart-kidney transplantation and simultaneous heart-liver transplantation and posttransplantation management; and (4) to explore the ethics of multiorgan transplantation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37439224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37439224</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001155>10.1161/CIR.0000000000001155</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37439224</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Michelle M Kittleson</dc:creator><dc:creator> Kavita S Sharma</dc:creator><dc:creator> Daniel C Brennan</dc:creator><dc:creator> Xingxing S Cheng</dc:creator><dc:creator> Sheryl L Chow</dc:creator><dc:creator> Monica Colvin</dc:creator><dc:creator> Adam D DeVore</dc:creator><dc:creator> Shannon M Dunlay</dc:creator><dc:creator> Meg Fraser</dc:creator><dc:creator> Jacqueline Garonzik-Wang</dc:creator><dc:creator> Prateeti Khazanie</dc:creator><dc:creator> Kevin M Korenblat</dc:creator><dc:creator> Duc T Pham</dc:creator><dc:creator> American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Council on Lifelong Congenital Heart Disease and Heart Health in the Young</dc:creator><dc:date> 2023-07-13</dc:date><dc:source> Circulation</dc:source><dc:title> Dual-Organ Transplantation: Indications, Evaluation, and Outcomes for Heart-Kidney and Heart-Liver Transplantation: A Scientific Statement From the American Heart Association</dc:title><dc:identifier> pmid:37439224</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001155</dc:identifier></item><item><title> Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37439219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Jul 13. doi: 10.1161/CIRCULATIONAHA.123.064521. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: ST-segment-elevation myocardial infarction (STEMI) guidelines recommend pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is unavailable. Full-dose tenecteplase is associated with an increased risk of intracranial hemorrhage in older patients. Whether pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients with STEMI is unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: STREAM-2 (Strategic Reperfusion in Elderly Patients Early After Myocardial Infarction) was an investigator-initiated, open-label, randomized, multicenter study. Patients ≥60 years of age with ≥2 mm ST-segment elevation in 2 contiguous leads, unable to undergo primary PCI within 1 hour, were randomly assigned (2:1) to half-dose tenecteplase followed by coronary angiography and PCI (if indicated) 6 to 24 hours after randomization, or to primary PCI. Efficacy end points of primary interest were ST resolution and the 30-day composite of death, shock, heart failure, or reinfarction. Safety assessments included stroke and nonintracranial bleeding. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Patients were assigned to pharmaco-invasive treatment (n=401) or primary PCI (n=203). Median times from randomization to tenecteplase or sheath insertion were 10 and 81 minutes, respectively. After last angiography, 85.2% of patients undergoing pharmaco-invasive treatment and 78.4% of patients undergoing primary PCI had ≥50% resolution of ST-segment elevation; their residual median sums of ST deviations were 4.5 versus 5.5 mm, respectively. Thrombolysis In Myocardial Infarction flow grade 3 at last angiography was ≈87% in both groups. The composite clinical end point occurred in 12.8% (51/400) of patients undergoing pharmaco-invasive treatment and 13.3% (27/203) of patients undergoing primary PCI (relative risk, 0.96 [95% CI, 0.62-1.48]). Six intracranial hemorrhages occurred in the pharmaco-invasive arm (1.5%): 3 were protocol violations (excess anticoagulation in 2 and uncontrolled hypertension in 1). No intracranial bleeding occurred in the primary PCI arm. The incidence of major nonintracranial bleeding was low in both groups (&lt;1.5%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT02777580.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37439219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37439219</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064521>10.1161/CIRCULATIONAHA.123.064521</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37439219</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Frans Van de Werf</dc:creator><dc:creator> Arsen D Ristić</dc:creator><dc:creator> Oleg V Averkov</dc:creator><dc:creator> Alexandra AriasMendoza</dc:creator><dc:creator> Yves Lambert</dc:creator><dc:creator> José F Kerr Saraiva</dc:creator><dc:creator> Pablo Sepulveda</dc:creator><dc:creator> Fernando Rosell-Ortiz</dc:creator><dc:creator> John K French</dc:creator><dc:creator> Ljilja B Musić</dc:creator><dc:creator> Katleen Vandenberghe</dc:creator><dc:creator> Kris Bogaerts</dc:creator><dc:creator> Cynthia M Westerhout</dc:creator><dc:creator> Alain Pagès</dc:creator><dc:creator> Thierry Danays</dc:creator><dc:creator> Kevin R Bainey</dc:creator><dc:creator> Peter Sinnaeve</dc:creator><dc:creator> Patrick Goldstein</dc:creator><dc:creator> Robert C Welsh</dc:creator><dc:creator> Paul W Armstrong</dc:creator><dc:creator> STREAM-2 Investigators</dc:creator><dc:date> 2023-07-13</dc:date><dc:source> Circulation</dc:source><dc:title> Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial</dc:title><dc:identifier> pmid:37439219</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064521</dc:identifier></item><item><title> Cumulative Risk Factor Exposure in Early Life</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):e19. doi: 10.1016/j.jacc.2023.04.055.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37438013</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.04.055>10.1016/j.jacc.2023.04.055</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438013</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Ramdas G Pai</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Cumulative Risk Factor Exposure in Early Life</dc:title><dc:identifier> pmid:37438013</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.055</dc:identifier></item><item><title> Risk of Left Atrial Thrombus in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):278-279. doi: 10.1016/j.jacc.2023.05.021.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37438012</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.021>10.1016/j.jacc.2023.05.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438012</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Daniel R Burczak</dc:creator><dc:creator> Raghav R Julakanti</dc:creator><dc:creator> Abdalla Kara Balla</dc:creator><dc:creator> Christopher G Scott</dc:creator><dc:creator> Jeffrey B Geske</dc:creator><dc:creator> Steve R Ommen</dc:creator><dc:creator> Vuyisile T Nkomo</dc:creator><dc:creator> Bernard J Gersh</dc:creator><dc:creator> Peter A Noseworthy</dc:creator><dc:creator> Konstantinos C Siontis</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Risk of Left Atrial Thrombus in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation</dc:title><dc:identifier> pmid:37438012</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.021</dc:identifier></item><item><title> Avoiding Stroke in Patients Undergoing Endovascular Aortic Arch Repair: JACC Review Topic of the Week</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230717124024&amp;v=2.17.9.post6+86293ac<description> As the bottleneck of endovascular aortic arch repair, early postoperative stroke remains a devastating complication in high-risk patients and a critical concern for the development of optimal endovascular techniques and devices. The incidence of early postoperative stroke varies widely among currently available endovascular techniques and devices, with reported rates ranging from 0.0% to 42.9%, and is significantly influenced by the severity of the patient&#39;s preexisting aortic atherosclerotic... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):265-277. doi: 10.1016/j.jacc.2023.04.053.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> As the bottleneck of endovascular aortic arch repair, early postoperative stroke remains a devastating complication in high-risk patients and a critical concern for the development of optimal endovascular techniques and devices. The incidence of early postoperative stroke varies widely among currently available endovascular techniques and devices, with reported rates ranging from 0.0% to 42.9%, and is significantly influenced by the severity of the patient&#39;s preexisting aortic atherosclerotic burden, air released from the endovascular device, and a variety of factors leading to cerebral perfusion insufficiency. Currently, preidentification of high-risk patients and careful perioperative management appear to play a critical role in reducing stroke incidence. Specific intraoperative prevention methods are still lacking, but embolic protection devices and carbon dioxide or high-volume saline flushing of endovascular devices appear promising. Detailed preoperative stroke risk stratification and screening for optimal endovascular techniques and devices for aortic arch treatment are unmet clinical needs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230717124024&v=2.17.9.post6+86293ac">37438011</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.04.053>10.1016/j.jacc.2023.04.053</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438011</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Long Cao</dc:creator><dc:creator> Hongpeng Zhang</dc:creator><dc:creator> Yangyang Ge</dc:creator><dc:creator> Wei Guo</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Avoiding Stroke in Patients Undergoing Endovascular Aortic Arch Repair: JACC Review Topic of the Week</dc:title><dc:identifier> pmid:37438011</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.053</dc:identifier></item></channel></rss>